标题
Systemic therapy of advanced hepatocellular carcinoma
作者
关键词
-
出版物
Future Oncology
Volume -, Issue -, Pages -
出版商
Future Medicine Ltd
发表日期
2020-12-14
DOI
10.2217/fon-2020-0758
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).
- (2020) Peter R. Galle et al. JOURNAL OF CLINICAL ONCOLOGY
- Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC).
- (2020) Arndt Vogel et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
- (2020) Robin K. Kelley et al. ADVANCES IN THERAPY
- Global incidence trends in primary liver cancer by age at diagnosis, sex, region, and etiology, 1990‐2017
- (2020) Zhenqiu Liu et al. CANCER
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).
- (2019) Max W. Sung et al. JOURNAL OF CLINICAL ONCOLOGY
- GS-09-Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology from two randomised, placebo-controlled phase 3 studies (REACH-2 and REACH)
- (2019) Peter Galle et al. JOURNAL OF HEPATOLOGY
- Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment
- (2019) Sarah Berhane et al. BRITISH JOURNAL OF CANCER
- 754PEffect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the CELESTIAL study
- (2019) N Freemantle et al. ANNALS OF ONCOLOGY
- LBA15_PRA phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)
- (2019) K Fizazi et al. ANNALS OF ONCOLOGY
- GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis
- (2019) Jan Best et al. Clinical Gastroenterology and Hepatology
- Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response‐Based Approach
- (2019) Guohong Han et al. HEPATOLOGY
- Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma
- (2019) Arndt Vogel et al. CANCER TREATMENT REVIEWS
- Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma
- (2019) Angel Alsina et al. Liver Cancer
- EASL Clinical Practice Guidelines: Management of alcohol-related liver disease
- (2018) Mark Thursz et al. JOURNAL OF HEPATOLOGY
- Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
- (2018) Richard S. Finn et al. JOURNAL OF HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Combinations of Bevacizumab With Cancer Immunotherapy
- (2018) Daniel S. Chen et al. CANCER JOURNAL
- Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
- (2018) Giorgia Marisi et al. WORLD JOURNAL OF GASTROENTEROLOGY
- 702POutcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC)
- (2018) R K Kelley et al. ANNALS OF ONCOLOGY
- Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials
- (2017) Richard Jackson et al. JOURNAL OF CLINICAL ONCOLOGY
- Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study
- (2017) Kim A. Reiss et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
- (2017) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
- (2017) Riccardo Lencioni et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib
- (2017) Tim Meyer et al. LIVER INTERNATIONAL
- Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
- (2016) Jorge A. Marrero et al. JOURNAL OF HEPATOLOGY
- Hepatocellular carcinoma
- (2016) Josep M. Llovet et al. Nature Reviews Disease Primers
- A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer
- (2013) L. Kadalayil et al. ANNALS OF ONCOLOGY
- The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma
- (2013) Wolfgang Sieghart et al. HEPATOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More